Astellas secures option to license immuno-oncology candidate DAX-044 from Audax

what happened

Astellas Pharma and Australia's Audax Biosciences have signed an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology candidate built on its AVIKINE technology. If Astellas exercises the option, it will gain worldwide rights to develop, manufacture and commercialize the drug. Audax, for its part, may co-fund and co-promote DAX-044 in Australia and New Zealand.

Audax will keep funding development and move the drug into a Phase 1 study, which is expected to start in 2027. Audax will receive upfront and option exercise payments totaling $285 million, plus milestone payments of up to $1.05 billion. Total potential transaction value is up to $1.34 billion, excluding royalties. The information is based on TradingView, citing a PRNewswire press release.

why it matters

For markets this is a targeted deal: it involves an early-stage drug rather than the company's overall revenue. It matters to Astellas investors as a step up in its immuno-oncology push, which the company lists among its main R&D priorities. Most of the payments depend on future stages and possible approval, so no immediate impact on financial results should be expected.

tags

instruments